Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

Pérol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB.

Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.


Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P.

Cancer. 2015 Mar 15;121(6):883-92. doi: 10.1002/cncr.29132. Epub 2014 Nov 6.


A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.

Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A.

J Thorac Oncol. 2014 Oct;9(10):1532-9. doi: 10.1097/JTO.0000000000000273.


Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M.

Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.


Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells.

Scheid JF, Mouquet H, Kofer J, Yurasov S, Nussenzweig MC, Wardemann H.

Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18044-8. doi: 10.1073/pnas.1113395108. Epub 2011 Oct 24.


Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors.

Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L.

Clin Cancer Res. 2011 Feb 1;17(3):611-9. doi: 10.1158/1078-0432.CCR-10-1731. Epub 2010 Dec 2.


Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.

Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H.

J Immunol Methods. 2008 Jan 1;329(1-2):112-24. Epub 2007 Oct 31. Erratum in: J Immunol Methods. 2008 May 20;334(1-2):142.


Regulation of autoreactive antibodies.

Yurasov S, Nussenzweig MC.

Curr Opin Rheumatol. 2007 Sep;19(5):421-6. Review.


Autoreactivity in human IgG+ memory B cells.

Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H.

Immunity. 2007 Feb;26(2):205-13.


Persistent expression of autoantibodies in SLE patients in remission.

Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Wardemann H, Nussenzweig MC.

J Exp Med. 2006 Oct 2;203(10):2255-61. Epub 2006 Sep 11.


B-cell tolerance checkpoints in healthy humans and patients with systemic lupus erythematosus.

Yurasov S, Hammersen J, Tiller T, Tsuiji M, Wardemann H.

Ann N Y Acad Sci. 2005 Dec;1062:165-74. Review.


A checkpoint for autoreactivity in human IgM+ memory B cell development.

Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H.

J Exp Med. 2006 Feb 20;203(2):393-400. Epub 2006 Jan 30.


Defective B cell tolerance checkpoints in systemic lupus erythematosus.

Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC.

J Exp Med. 2005 Mar 7;201(5):703-11. Epub 2005 Feb 28.


Predominant autoantibody production by early human B cell precursors.

Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC.

Science. 2003 Sep 5;301(5638):1374-7. Epub 2003 Aug 14.


Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.

Strayer DS, Pomerantz RJ, Yu M, Rosenzweig M, BouHamdan M, Yurasov S, Johnson RP, Goldstein H.

Gene Ther. 2000 May;7(10):886-95.


Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication.

Browning Paul J, Wang EJ, Pettoello-Mantovani M, Raker C, Yurasov S, Goldstein MM, Horner JW, Chan J, Goldstein H.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):481-92.


thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues.

Pettoello-Mantovani M, Kollmann TR, Katopodis NF, Raker C, Kim A, Yurasov S, Wiltshire H, Goldstein H.

J Infect Dis. 1998 Feb;177(2):337-46.


Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection.

Browning J, Horner JW, Pettoello-Mantovani M, Raker C, Yurasov S, DePinho RA, Goldstein H.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14637-41.


Low Density Mononuclear Cells from Umbilical Cord Blood as a Target for Retrovirally Mediated Gene Transfer.

Yurasov SV, Flasshove M, Vladimirskaya EB, Rumyantsev AG, Moore MA.

Russ J Immunol. 1996 Dec;1(1):35-40.


SCID-hu mice: a model for studying disseminated HIV infection.

Goldstein H, Pettoello-Mantovani M, Katopodis NF, Kim A, Yurasov S, Kollmann TR.

Semin Immunol. 1996 Aug;8(4):223-31. Review.


Density enrichment and characterization of hematopoietic progenitors and stem cells from umbilical cord blood.

Yurasov SV, Flasshove M, Rafii S, Moore MA.

Bone Marrow Transplant. 1996 Apr;17(4):517-25.


Supplemental Content

Loading ...
Support Center